Heinz Wiendl

List of Publications by Year
in descending order

450 papers	21,555 citations	7568 77 h-index	19749 117 g-index
462 all docs	462 docs citations	462 times ranked	23167 citing authors

#	Article	IF	Citations
1	A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. Brain, 2023, 146, 977-990.	7.6	10
2	Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Multiple Sclerosis Journal, 2022, 28, 257-268.	3.0	35
3	Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Multiple Sclerosis Journal, 2022, 28, 910-924.	3.0	27
4	K2P18.1 translates T cell receptor signals into thymic regulatory T cell development. Cell Research, 2022, 32, 72-88.	12.0	14
5	Efficacy and safety of ocrelizumab in patients with relapsingâ€remitting multiple sclerosis with suboptimal response to prior diseaseâ€modifying therapies: A primary analysis from the phase 3b CASTING singleâ€arm, openâ€label trial. European Journal of Neurology, 2022, 29, 790-801.	3.3	15
6	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. Multiple Sclerosis and Related Disorders, 2022, 57, 103389.	2.0	6
7	Neuropsychological Performance in Autoimmune Limbic Encephalitis: Evidence from an Immunotherapy-NaÃ¯ve Cohort. Archives of Clinical Neuropsychology, 2022, 37, 738-752.	0.5	6
8	How patients with multiple sclerosis acquire disability. Brain, 2022, 145, 3147-3161.	7.6	126
9	Bilaterality of temporal EEG findings in limbic encephalitis compared to other mesiotemporal epilepsies â€“ a retrospective cohort study. Seizure: the Journal of the British Epilepsy Association, 2022, 96, 98-101.	2.0	0
10	Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain, 2022, 145, 1711-1725.	7.6	23
11	Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. Frontiers in Neurology, 2022, 13, 828616.	2.4	4
12	Stroke induces disease-specific myeloid cells in the brain parenchyma and pia. Nature Communications, 2022, 13, 945.	12.8	40
13	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
14	Impact of diseaseâ€modifying therapies on humoral and cellular immuneâ€responses following SARSâ€CoVâ€2 vaccination in MS patients. Clinical and Translational Science, 2022, 15, 1606-1612.	3.1	5
15	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5â€‰years. Multiple Sclerosis Journal, 2022, 28, 1576-1590.	3.0	24
16	Eculizumab versus rituximab in generalised myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 548-554.	1.9	19
17	Next-generation antibody-based therapies in neurology. Brain, 2022, 145, 1229-1241.	7.6	11
18	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurology, The, 2022, 21, 608-619.	10.2	44

#	Article	IF	Citations
19	Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas. Scientific Reports, 2022, 12, 6769.	3.3	10
20	023â€... Relapse outcomes with natalizumab Q4W vs switch to Q6W. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.3-A21.	1.9	0
21	Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2151-2153.	3.0	7
22	What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?. Neurotherapeutics, 2022, 19, 785-807.	4.4	10
23	High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients. Multiple Sclerosis Journal, 2021, 27, 1491-1496.	3.0	5
24	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri^{Â®} Observational Program (TOP). Multiple Sclerosis Journal, 2021, 27, 410-419.	3.0	7
25	Real-world disability improvement in patients with relapsingâ€“remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Multiple Sclerosis Journal, 2021, 27, 719-728.	3.0	15
26	Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology, 2021, 96, e610-e618.	1.1	46
27	Patients with a relapsing course of steroidâ€responsive encephalopathy associated with autoimmune thyroiditis exhibit persistent intrathecal CD4+ Tâ€cell activation. European Journal of Neurology, 2021, 28, 1284-1291.	3.3	4
28	Dysphagia in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease as a surrogate of brain involvement?. European Journal of Neurology, 2021, 28, 1765-1770.	3.3	10
29	Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity, 2021, 54, 164-175.e6.	14.3	119
30	Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from theÂImplementation of the Multicenter REGIMS Registry. Drug Safety, 2021, 44, 7-15.	3.2	5
31	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110396.	3.5	86
32	Detecting myasthenia gravis as a cause of unclear dysphagia with an endoscopic tensilon test. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110355.	3.5	6
33	Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.5	11
34	Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation. Multiple Sclerosis Journal, 2021, 27, 2062-2076.	3.0	25
35	Immune Cell Infiltration into the Brain After Ischemic Stroke in Humans Compared to Mice and Rats: a Systematic Review and Meta-Analysis. Translational Stroke Research, 2021, 12, 976-990.	4.2	35
36	Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199737.	3.5	4

#	Article	IF	Citations
37	Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. Brain Communications, 2021, 3, fcab157.	3.3	25
38	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1007-1013.	1.9	22
39	Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy. Muscle and Nerve, 2021, 63, 874-880.	2.2	8
40	Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibodyâ€“Positive Generalized Myasthenia Gravis. Expert Opinion on Investigational Drugs, 2021, 30, 483-493.	4.1	32
41	Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity. Brain, 2021, 144, 1152-1166.	7.6	28
42	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	3.6	47
43	Classification of neurological diseases using multi-dimensional CSF analysis. Brain, 2021, 144, 2625-2634.	7.6	22
44	The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome. Journal of Clinical Immunology, 2021, 41, 1229-1240.	3.8	5
45	Characterization of Extracranial Giant Cell Arteritis with Intracranial Involvement and its Rapidly Progressive Subtype. Annals of Neurology, 2021, 90, 118-129.	5.3	10
46	Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases. Nature Reviews Neurology, 2021, 17, 433-447.	10.1	9
47	Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis. International Journal of Molecular Sciences, 2021, 22, 5755.	4.1	14
48	Occurrence of status epilepticus in persons with epilepsy is determined by sex, epilepsy classification, and etiology: a single center cohort study. Journal of Neurology, 2021, 268, 4816-4823.	3.6	6
49	Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2021, 10, 803-818.	3.2	2
50	Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015â€“2020. Drugs, 2021, 81, 1031-1063.	10.9	19
51	Determinants of cognition in autoimmune limbic encephalitisâ€”A retrospective cohort study. Hippocampus, 2021, 31, 1092-1103.	1.9	7
52	Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges. Nature Neuroscience, 2021, 24, 1225-1234.	14.8	103
53	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	65
54	Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses. Molecular Psychiatry, 2021, 26, 7661-7670.	7.9	18

#	Article	IF	Citations
55	Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. Neurological Research and Practice, 2021, 3, 44.	2.0	9
56	Bcl6 controls meningeal Th17â€“B cell interaction in murine neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	13
57	Longer-Term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis. Neurology, 2021, 97, 10.1212/WNL.0000000000012716.	1.1	0
58	NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Cells, 2021, 10, 2551.	4.1	8
59	Diagnostic utility of cerebrospinal fluid (CSF) findings in seizures and epilepsy with and without autoimmune-associated disease. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 233-243.	2.0	8
60	Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. Brain, 2021, 144, 3126-3141.	7.6	14
61	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity scoreâ€“matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110424.	3.5	9
62	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	38
63	CT Hypoperfusion-Hypodensity Mismatch to Identify Patients With Acute Ischemic Stroke Within 4.5 Hours of Symptom Onset. Neurology, 2021, 97, e2088-e2095.	1.1	5
64	Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	24
65	Impact of T cells on neurodegeneration in antiâ€GAD65 limbic encephalitis. Annals of Clinical and Translational Neurology, 2021, 8, 2289-2301.	3.7	10
66	Detecting Myositis as a Cause of Unexplained Dysphagia: Proposal of a Diagnostic Algorithm. European Journal of Neurology, 2021, , .	3.3	2
67	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110582.	3.5	9
68	Long-Term Sonographical Follow-Up of Arterial Stenosis Due to Spontaneous Cervical Artery Dissection. Frontiers in Neurology, 2021, 12, 792321.	2.4	4
69	Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents. Annals of Neurology, 2020, 87, 40-51.	5.3	69
70	A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e638.	6.0	5
71	Serial position effects rapidly distinguish Alzheimerâ€™s from frontotemporal dementia. Journal of Neurology, 2020, 267, 975-983.	3.6	4
72	Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nature Reviews Neurology, 2020, 16, 56-62.	10.1	71

#	Article	IF	Citations
73	Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	34
74	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Multiple Sclerosis Journal, 2020, 26, 1866-1876.	3.0	16
75	Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses. Journal of Clinical Medicine, 2020, 9, 35.	2.4	13
76	The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 2150.	2.4	41
77	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971.	10.2	85
78	Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine, 2020, 383, 546-557.	27.0	358
79	Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015â€“2020. BioDrugs, 2020, 34, 587-610.	4.6	12
80	The Agony of Choice? Preserved Affective Decision Making in Early Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 914.	2.4	1
81	Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. Neurology, 2020, 95, 505-505.	1.1	1
82	Blood and cerebrospinal fluid immune cell profiles in patients with temporal lobe epilepsy of different etiologies. Epilepsia, 2020, 61, e153-e158.	5.1	12
83	Immune signatures of prodromal multiple sclerosis in monozygotic twins. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21546-21556.	7.1	36
84	MCAM/CD146 Signaling via PLCÎ³1 Leads to Activation of Î²1-Integrins in Memory T-Cells Resulting in Increased Brain Infiltration. Frontiers in Immunology, 2020, 11, 599936.	4.8	9
85	The STING-IFN-Î²-Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 9249.	4.1	11
86	Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091178.	3.5	16
87	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 681-686.	1.9	66
88	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 2020, 56, 102807.	6.1	67
89	Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e654.	6.0	26
90	Is APOE Îµ4 associated with cognitive performance in early MS?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e728.	6.0	11

#	Article	IF	Citations
91	Next-Generation Neuroimmunology: New Technologies to Understand Central Nervous System Autoimmunity. Trends in Immunology, 2020, 41, 341-354.	6.8	14
92	TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. Neuro-Oncology, 2020, 22, 1030-1043.	1.2	35
93	Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions. International Journal of Molecular Sciences, 2020, 21, 2046.	4.1	5
94	Neurological immunotherapy in the era of COVID-19 â€" looking for consensus in the literature. Nature Reviews Neurology, 2020, 16, 493-505.	10.1	57
95	Expert opinion on the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093501.	3.5	23
96	4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect â€“ No. Multiple Sclerosis Journal, 2020, 26, 1311-1312.	3.0	1
97	Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	18
98	Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nature Communications, 2020, 11, 247.	12.8	242
99	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal of the Neurological Sciences, 2020, 412, 116803.	0.6	110
100	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 660-668.	1.9	97
101	Ocrelizumab initiation in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	26
102	Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis. Journal of Neuroimmunology, 2020, 341, 577171.	2.3	17
103	Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?. Journal of Neuroimmunology, 2019, 329, 1-8.	2.3	11
104	Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study. EBioMedicine, 2019, 46, 381-386.	6.1	14
105	EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases. PLoS ONE, 2019, 14, e0223886.	2.5	10
106	Impact of FcÎ³R variants on the response to alemtuzumab in multiple sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 2586-2594.	3.7	4
107	Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. Neurology, 2019, 93, 550-554.	1.1	13
108	Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain, 2019, 142, 3411-3427.	7.6	39

#	Article	IF	Citations
109	Resolving the cognitive clinico-radiological paradox â€“ Microstructural degeneration of fronto-striatal-thalamic loops in early active multiple sclerosis. Cortex, 2019, 121, 239-252.	2.4	11
110	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
111	Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies. Frontiers in Immunology, 2019, 10, 515.	4.8	26
112	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Science Translational Medicine, 2019, 11, .	12.4	92
113	An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis. Frontiers in Neurology, 2019, 10, 178.	2.4	2
114	A fatal case of daclizumab-induced liver failure in a patient with MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e539.	6.0	11
115	Prominent T-Cell Responses against the Acetylcholine Receptor Îµ Subunit in Myasthenia Gravis. Neurology Research International, 2019, 2019, 1-5.	1.3	0
116	Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641983657.	3.5	83
117	VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells. International Immunology, 2019, 31, 407-412.	4.0	14
118	Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. BMJ Open, 2019, 9, e030309.	1.9	63
119	Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response. Neurological Research and Practice, 2019, 1, 40.	2.0	4
120	Ineffective treatment of PML with pembrolizumab. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e627.	6.0	39
121	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, 2019, 10, 5779.	12.8	87
122	Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination. International Journal of Molecular Sciences, 2019, 20, 5985.	4.1	8
123	Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 271-276.	7.1	40
124	Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. Journal of Neurology, 2019, 266, 165-173.	3.6	20
125	Apraxia screening predicts Alzheimer pathology in frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 562-569.	1.9	6
126	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). Journal of Neurology, 2019, 266, 386-397.	3.6	24

#	Article	IF	Citations
127	Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 661-668.	3.0	12
128	The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis. Neural Regeneration Research, 2019, 14, 1950.	3.0	28
129	Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells. Cell Reports, 2018, 22, 2094-2106.	6.4	60
130	Mechanisms underlying lesion development and lesion distribution in <scp>CNS</scp> autoimmunity. Journal of Neurochemistry, 2018, 146, 122-132.	3.9	24
131	Sex bias in MHC I-associated shaping of the adaptive immune system. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2168-2173.	7.1	51
132	Defining response profiles after alemtuzumab. Neurology, 2018, 90, 309-311.	1.1	15
133	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	3.0	458
134	Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e446.	6.0	54
135	Skeletal muscle cells actively shape (auto)immune responses. Autoimmunity Reviews, 2018, 17, 518-529.	5.8	74
136	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis Journal, 2018, 24, 963-973.	3.0	79
137	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Multiple Sclerosis Journal, 2018, 24, 1883-1891.	3.0	2
138	Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters. Multiple Sclerosis Journal, 2018, 24, 563-573.	3.0	28
139	Circulating lymphocyte levels and relationship with infection status in patients with relapsingâ€“remitting multiple sclerosis treated with daclizumab beta. Multiple Sclerosis Journal, 2018, 24, 1725-1736.	3.0	3
140	Relevance of raised cerebrospinal fluid monocyte levels in patients with frontotemporal dementia. Neurobiology of Aging, 2018, 62, 45-52.	3.1	6
141	085â€…Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri^{Â®} observational program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A34.2-A34.	1.9	0
142	Vitiligo after alemtuzumab treatment. Neurology, 2018, 91, e2233-e2237.	1.1	35
143	Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis. NeuroSignals, 2018, 26, 77-93.	0.9	22
144	Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease. Frontiers in Neurology, 2018, 9, 1081.	2.4	91

#	Article	IF	Citations
145	Dietary salt promotes ischemic brain injury and is associated with parenchymal migrasome formation. PLoS ONE, 2018, 13, e0209871.	2.5	28
146	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
147	Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis. Frontiers in Neurology, 2018, 9, 658.	2.4	8
148	Apraxia profilesâ€"A single cognitive marker to discriminate all variants of frontotemporal lobar degeneration and Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 363-371.	2.4	16
149	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders, 2018, 24, 11-19.	2.0	17
150	Amygdala enlargement and emotional responses in (autoimmune) temporal lobe epilepsy. Scientific Reports, 2018, 8, 9561.	3.3	15
151	Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluidâ€"Results from the ToFingo Successor Study. Frontiers in Immunology, 2018, 9, 1560.	4.8	24
152	Nur77 serves as a molecular brake of the metabolic switch during T cell activation to restrict autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8017-E8026.	7.1	93
153	Primary angiitis of the central nervous system: diagnosis and treatment. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878507.	3.5	74
154	Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging. Journal of Neurology, 2018, 265, 2284-2294.	3.6	4
155	A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation. Frontiers in Neurology, 2018, 9, 383.	2.4	6
156	Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System. Frontiers in Neurology, 2018, 9, 407.	2.4	13
157	Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer. Oxford Medical Case Reports, 2018, 2018, omy034.	0.4	3
158	Immunophenotyping of cerebrospinal fluid cells by Chipcytometry. Journal of Neuroinflammation, 2018, 15, 160.	7.2	13
159	Defining mechanisms of neural plasticity after brainstem ischemia in rats. Annals of Neurology, 2018, 83, 1003-1015.	5.3	6
160	Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3. BMC Biology, 2018, 16, 47.	3.8	23
161	Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination. Brain Structure and Function, 2018, 223, 3091-3106.	2.3	16
162	Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus. Journal of Neuroinflammation, 2018, 15, 236.	7.2	38

#	Article	IF	Citations
163	The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disordersâ€"A Systematic Review. Frontiers in Immunology, 2018, 9, 1731.	4.8	130
164	Impairment of frequency-specific responses associated with altered electrical activity patterns in auditory thalamus following focal and general demyelination. Experimental Neurology, 2018, 309, 54-66.	4.1	15
165	Immune cell profiling in the cerebrospinal fluid of patients with primary angiitis of the central nervous system reflects the heterogeneity of the disease. Journal of Neuroimmunology, 2018, 321, 109-116.	2.3	16
166	Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. Multiple Sclerosis Journal, 2018, 24, 1871-1882.	3.0	21
167	Reply to Liu et al.: Haplotype matters: CD226 polymorphism as a potential trigger for impaired immune regulation in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E908-E909.	7.1	3
168	Natalizumab-associated PML. Neurology, 2017, 88, 1197-1205.	1.1	102
169	Endothelial Basement Membrane Laminin 511 Contributes to Endothelial Junctional Tightness and Thereby Inhibits Leukocyte Transmigration. Cell Reports, 2017, 18, 1256-1269.	6.4	125
170	CT versus MR Techniques in the Detection of Cervical Artery Dissection. Journal of Neuroimaging, 2017, 27, 607-612.	2.0	41
171	NMO Spectrum Disorders. Neurology International Open, 2017, 01, E36-E47.	0.4	3
172	Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?. Autoimmunity Reviews, 2017, 16, 478-494.	5.8	21
173	Targeting Different Monocyte/Macrophage Subsets Has No Impact on Outcome in Experimental Stroke. Stroke, 2017, 48, 1061-1069.	2.0	42
174	Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e307.	6.0	39
175	Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis. Journal of Neuroimmunology, 2017, 313, 125-128.	2.3	10
176	Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?. Neurology, 2017, 89, 1098-1100.	1.1	14
177	Benefitâ€"Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. Drugs, 2017, 77, 1755-1768.	10.9	49
178	Distinct cognitive impairments in different disease courses of multiple sclerosisâ€"A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2017, 83, 568-578.	6.1	83
179	Cladribine â€" an old newcomer for pulsed immune reconstitution in MS. Nature Reviews Neurology, 2017, 13, 573-574.	10.1	36
180	Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier. Journal of Visualized Experiments, 2017, , .	0.3	3

#	Article	IF	Citations
181	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 32-40.	2.0	9
182	Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets. Multiple Sclerosis Journal, 2017, 23, 1025-1030.	3.0	30
183	14â€3â€3 Proteins regulate K_{2P}5.1 surface expression on T lymphocytes. Traffic, 2017, 18, 29-43.	2.7	17
184	Targeting B cells in relapsingâ€“remitting multiple sclerosis: from pathophysiology to optimal clinical management. Therapeutic Advances in Neurological Disorders, 2017, 10, 51-66.	3.5	62
185	The quality of cortical network function recovery depends on localization and degree of axonal demyelination. Brain, Behavior, and Immunity, 2017, 59, 103-117.	4.1	25
186	Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. OncoImmunology, 2017, 6, e1250050.	4.6	86
187	Treating refractory post-herpetic anti-N-methyl-d-aspartate receptor encephalitis with rituximab. Oxford Medical Case Reports, 2017, 2017, omx034.	0.4	4
188	Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. Annals of Clinical and Translational Neurology, 2017, 4, 909-914.	3.7	11
189	<scp>NMDAR</scp> encephalitis: passive transfer from man to mouse by a recombinant antibody. Annals of Clinical and Translational Neurology, 2017, 4, 768-783.	3.7	101
190	Gutâ€“CNS-Axis as Possibility to Modulate Inflammatory Disease Activityâ€”Implications for Multiple Sclerosis. International Journal of Molecular Sciences, 2017, 18, 1526.	4.1	37
191	An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function. Frontiers in Neurology, 2017, 8, 517.	2.4	5
192	Cortex Parcellation Associated Whole White Matter Parcellation in Individual Subjects. Frontiers in Human Neuroscience, 2017, 11, 352.	2.0	7
193	Novel pathomechanisms in inflammatory neuropathies. Journal of Neuroinflammation, 2017, 14, 232.	7.2	29
194	Can cognitive assessment really discriminate early stages of Alzheimerâ€™s and behavioural variant frontotemporal dementia at initial clinical presentation?. Alzheimer's Research and Therapy, 2017, 9, 61.	6.2	39
195	Î±4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e388.	6.0	25
196	Liver X receptor activation promotes differentiation of regulatory T cells. PLoS ONE, 2017, 12, e0184985.	2.5	39
197	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. Frontiers in Immunology, 2016, 7, 606.	4.8	88
198	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). PLoS ONE, 2016, 11, e0144834.	2.5	8

#	Article	IF	Citations
199	Evidence of a pathogenic role for CD8 ⁺ T cells in anti-GABA _B receptor limbic encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e232.	6.0	46
200	Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis. Human Brain Mapping, 2016, 37, 1866-1879.	3.6	55
201	CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. Nature Communications, 2016, 7, 11153.	12.8	98
202	Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nature Communications, 2016, 7, 11626.	12.8	105
203	ALAIN01â€"Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. BMC Neurology, 2016, 16, 34.	1.8	13
204	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	1.6	33
205	Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010â€"2015. Expert Review of Neurotherapeutics, 2016, 16, 689-700.	2.8	14
206	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2973-82.	7.1	157
207	B7-H1 shapes T-cellâ€"mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6182-E6191.	7.1	24
208	The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. Acta Neuropathologica, 2016, 132, 413-431.	7.7	26
209	CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology, 2016, 87, 958-959.	1.1	7
210	Shared neural correlates of limb apraxia in early stages of Alzheimer's dementia and behavioural variant frontotemporal dementia. Cortex, 2016, 84, 1-14.	2.4	16
211	The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells. American Journal of Physiology - Cell Physiology, 2016, 311, C583-C595.	4.6	20
212	Diagnostic criteria for Susac syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1287-1295.	1.9	184
213	Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. Science Translational Medicine, 2016, 8, 364ra152.	12.4	94
214	Prothrombin and factor X are elevated in multiple sclerosis patients. Annals of Neurology, 2016, 80, 946-951.	5.3	35
215	Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease. Science Translational Medicine, 2016, 8, 362ra146.	12.4	48
216	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology, 2016, 87, 2491-2494.	1.1	18

#	Article	IF	Citations
217	Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS. Neurology, 2016, 87, 2380-2381.	1.1	15
218	Computed tomographyâ€“based quantification of lesion water uptake identifies patients within 4.5 hours of stroke onset: A multicenter observational study. Annals of Neurology, 2016, 80, 924-934.	5.3	88
219	Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e289.	6.0	84
220	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances, 2016, 2, e1501678.	10.3	133
221	Leitlinie Dermatomyositis â€“ Auszug aus der interdisziplinÃren S2kâ€Leitlinie zu Myositissyndromen der deutschen Gesellschaft fÂ¼r Neurologie. JDDG - Journal of the German Society of Dermatology, 2016, 14, e1.	0.8	0
222	Guidelines on dermatomyositis â€“ excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. JDDG - Journal of the German Society of Dermatology, 2016, 14, 321-338.	0.8	43
223	Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e183.	6.0	117
224	Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications. Neurotherapeutics, 2016, 13, 4-19.	4.4	29
225	Sodium chloride promotes pro-inflammatory macrophage polarization thereby aggravating CNS autoimmunity. Journal of Autoimmunity, 2016, 67, 90-101.	6.5	136
226	Immunoadsorption therapy in autoimmune encephalitides. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e207.	6.0	81
227	Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1235-1241.	3.0	16
228	Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. Journal of Neurology, 2016, 263, 1473-1494.	3.6	179
229	Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e195.	6.0	66
230	CD4+HLA-G+ regulatory T cells: Molecular signature and pathophysiological relevance. Human Immunology, 2016, 77, 727-733.	2.4	26
231	Highlights from the 31st ECTRIMS congress â€“ Barcelona 2015. Multiple Sclerosis Journal, 2016, 22, 7-10.	3.0	12
232	CD4⁺T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-Oncology, 2016, 18, 807-818.	1.2	129
233	PML risk stratification using anti-JCV antibody index and L-selectin. Multiple Sclerosis Journal, 2016, 22, 1048-1060.	3.0	62
234	Implications of dietary salt intake for multiple sclerosis pathogenesis. Multiple Sclerosis Journal, 2016, 22, 133-139.	3.0	22

#	Article	IF	Citations
235	A novel automated segmentation method for retinal layers in OCT images proves retinal degeneration after optic neuritis. British Journal of Ophthalmology, 2016, 100, 484-490.	3.9	9
236	Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration. Multiple Sclerosis Journal, 2016, 22, 73-84.	3.0	43
237	Therapie der Multiplen Sklerose. , 2016, , 55-93.		1
238	Dichoptic Metacontrast Masking Functions to Infer Transmission Delay in Optic Neuritis. PLoS ONE, 2016, 11, e0163375.	2.5	0
239	Fingolimod treatment promotes regulatory phenotype and function of B cells. Annals of Clinical and Translational Neurology, 2015, 2, 119-130.	3.7	82
240	Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 373-387.	3.7	57
241	Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimerâ€™s Dementia Based on Apraxia Profiles. Journal of Alzheimer's Disease, 2015, 49, 593-605.	2.6	36
242	An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices. Journal of Visualized Experiments, 2015, , .	0.3	1
243	The twoâ€pore domain K₂P channel TASK2 drives human NKâ€cell proliferation and cytolytic function. European Journal of Immunology, 2015, 45, 2602-2614.	2.9	12
244	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. Genetic Epidemiology, 2015, 39, 601-608.	1.3	15
245	Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells. International Journal of Molecular Sciences, 2015, 16, 16330-16346.	4.1	25
246	Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. International Journal of Molecular Sciences, 2015, 16, 16414-16439.	4.1	167
247	Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms. International Journal of Molecular Sciences, 2015, 16, 16880-16896.	4.1	4
248	Early and Degressive Putamen Atrophy in Multiple Sclerosis. International Journal of Molecular Sciences, 2015, 16, 23195-23209.	4.1	26
249	Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study. Frontiers in Neurology, 2015, 6, 167.	2.4	26
250	Impaired Autonomic Responses to Emotional Stimuli in Autoimmune Limbic Encephalitis. Frontiers in Neurology, 2015, 6, 250.	2.4	4
251	Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. Drugs, 2015, 75, 947-977.	10.9	31
252	Switching from natalizumab to fingolimod. Neurology, 2015, 85, 29-39.	1.1	110

#	Article	IF	Citations
253	Neurocognitive decline in HIV patients is associated with ongoing Tâ€cell activation in the cerebrospinal fluid. Annals of Clinical and Translational Neurology, 2015, 2, 906-919.	3.7	40
254	A human post-mortem brain model for the standardization of multi-centre MRI studies. NeuroImage, 2015, 110, 11-21.	4.2	30
255	Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1521-1532.	3.0	25
256	CD28 Superagonist-Mediated Boost of Regulatory T Cells Increases Thrombo-Inflammation and Ischemic Neurodegeneration during the Acute Phase of Experimental Stroke. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 6-10.	4.3	67
257	Therapeutic uses of anti-Î±4-integrin (anti-VLA-4) antibodies in multiple sclerosis. International Immunology, 2015, 27, 47-53.	4.0	50
258	Long-term efficacy of alemtuzumab in polymyositis. Rheumatology, 2015, 54, 560-562.	1.9	14
259	Optimizing therapy early in multiple sclerosis: An evidence-based view. Multiple Sclerosis and Related Disorders, 2015, 4, 460-469.	2.0	83
260	Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e70.	6.0	56
261	Recovery of thalamic microstructural damage after Shiga toxin 2-associated hemolyticâ€“uremic syndrome. Journal of the Neurological Sciences, 2015, 356, 175-183.	0.6	12
262	Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (â€œNeuroprotectionâ€). Neurotherapeutics, 2015, 12, 449-454.	4.4	25
263	FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1811-1822.	3.0	37
264	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2015, 373, 1418-1428.	27.0	245
265	Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system. Acta Neuropathologica, 2015, 130, 297-298.	7.7	7
266	B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Nonâ€“PD-1â€“Mediated Pathway. Journal of Immunology, 2015, 195, 3584-3595.	0.8	13
267	Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). BMC Neurology, 2015, 15, 96.	1.8	7
268	Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiology of Aging, 2015, 36, 81-89.	3.1	141
269	Apraxia profile differentiates behavioural variant frontotemporal from Alzheimer's dementia in mild disease stages. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 809-815.	1.9	22
270	Trafficking of lymphocytes into the CNS. Oncotarget, 2015, 6, 17863-17864.	1.8	5

#	Article	IF	Citations
271	The NKG2D - IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies. Oncotarget, 2015, 6, 43230-43243.	1.8	17
272	Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice. PLoS ONE, 2014, 9, e93280.	2.5	87
273	FoxP3+ Regulatory T Cells Determine Disease Severity in Rodent Models of Inflammatory Neuropathies. PLoS ONE, 2014, 9, e108756.	2.5	20
274	CD3-Positive B Cells: A Storage-Dependent Phenomenon. PLoS ONE, 2014, 9, e110138.	2.5	9
275	Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking. PLoS ONE, 2014, 9, e115920.	2.5	43
276	Human CD4 ⁺ HLAâ€G ⁺ regulatory T cells are potent suppressors of graftâ€versusâ€host disease in vivo. FASEB Journal, 2014, 28, 3435-3445.	0.5	51
277	VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. Journal of Experimental Medicine, 2014, 211, 1833-1846.	8.5	134
278	Response to Letter Regarding Article, â€œBlocking of Î±4 Integrin Does Not Protect From Acute Ischemic Stroke in Miceâ€. Stroke, 2014, 45, e196.	2.0	1
279	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1190-1197.	1.9	156
280	Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis. JAMA Neurology, 2014, 71, 905.	9.0	54
281	Teriflunomide and Its Mechanism of Action in Multiple Sclerosis. Drugs, 2014, 74, 659-674.	10.9	274
282	Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Annals of Neurology, 2014, 75, 739-758.	5.3	100
283	Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis. European Journal of Immunology, 2014, 44, 2295-2305.	2.9	28
284	Clinical Relevance of Brain Volume Measures in Multiple Sclerosis. CNS Drugs, 2014, 28, 147-156.	5.9	254
285	The Neuroinflammation Biobank in the Department of Neurology, University Hospital Muenster, Germany. Biopreservation and Biobanking, 2014, 12, 74-75.	1.0	3
286	Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. Therapeutic Advances in Neurological Disorders, 2014, 7, 137-149.	3.5	9
287	Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis. NeuroImage: Clinical, 2014, 6, 475-487.	2.7	38
288	Effects of Glatiramer Acetate in a Spontaneous Model of Autoimmune Neuroinflammation. American Journal of Pathology, 2014, 184, 2056-2065.	3.8	8

#	Article	IF	Citations
289	Blocking of Î±4 Integrin Does Not Protect From Acute Ischemic Stroke in Mice. Stroke, 2014, 45, 1799-1806.	2.0	78
290	Myelin Oligodendrocyte Glycoprotein (MOG₃₅₋₅₅) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice. Journal of Visualized Experiments, 2014, , .	0.3	110
291	Specific loss of cellular L-selectin on CD4+ T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. Aids, 2014, 28, 793-795.	2.2	20
292	Monoclonal antibodies in neuroinflammatory diseases. Expert Opinion on Biological Therapy, 2013, 13, 831-846.	3.1	14
293	Fine-Tuning of Regulatory T Cell Function: The Role of Calcium Signals and Naive Regulatory T Cells for Regulatory T Cell Deficiency in Multiple Sclerosis. Journal of Immunology, 2013, 190, 4965-4970.	0.8	52
294	Excitotoxic neuronal cell death during an oligodendrocyte-directed CD8+ T cell attack in the CNS gray matter. Journal of Neuroinflammation, 2013, 10, 121.	7.2	19
295	Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS. Nature Medicine, 2013, 19, 1161-1165.	30.7	136
296	4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis. Experimental Neurology, 2013, 248, 62-71.	4.1	22
297	Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood, 2013, 121, 679-691.	1.4	300
298	DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis. NeuroImage: Clinical, 2013, 2, 258-262.	2.7	31
299	Neurons as targets for T cells in the nervous system. Trends in Neurosciences, 2013, 36, 315-324.	8.6	88
300	Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. Journal of Neurology, 2013, 260, 1215-1233.	3.6	43
301	Modulation of IL-2RÎ± with daclizumab for treatment of multiple sclerosis. Nature Reviews Neurology, 2013, 9, 394-404.	10.1	71
302	Identification of two-pore domain potassium channels as potent modulators of osmotic volume regulation in human T lymphocytes. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 699-707.	2.6	23
303	CON: Regulatory T Cells Are Protective in Ischemic Stroke. Stroke, 2013, 44, e87-8.	2.0	20
304	An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Multiple Sclerosis Journal, 2013, 19, 1137-1144.	3.0	19
305	<scp>I</scp> -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology, 2013, 81, 865-871.	1.1	140
306	Rasmussen encephalitis treated with natalizumab. Neurology, 2013, 81, 395-397.	1.1	66

#	Article	IF	Citations
307	Dendritic cell vaccination in autoimmune disease. Current Opinion in Rheumatology, 2013, 25, 268-274.	4.3	31
308	Reprogramming the immune repertoire with alemtuzumab in MS. Nature Reviews Neurology, 2013, 9, 125-126.	10.1	53
309	Identification of Inflammatory Neuronal Injury and Prevention of Neuronal Damage in Multiple Sclerosis. JAMA Neurology, 2013, 70, 1569-74.	9.0	30
310	Thalamic involvement in patients with neurologic impairment due to Shiga toxin 2. Annals of Neurology, 2013, 73, 419-429.	5.3	13
311	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis Journal, 2013, 19, 1533-1538.	3.0	92
312	CD4+NKG2D+ T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation. PLoS ONE, 2013, 8, e81455.	2.5	28
313	Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis. PLoS ONE, 2013, 8, e77634.	2.5	40
314	Anti-JC-virus antibody prevalence in a German MS cohort. Multiple Sclerosis Journal, 2012, 18, 1054-1055.	3.0	13
315	Immune mechanisms of stroke. Current Opinion in Neurology, 2012, 25, 334-340.	3.6	71
316	Neuron-directed autoimmunity in the central nervous system. Current Opinion in Neurology, 2012, 25, 341-348.	3.6	19
317	Neuroinflammation. Current Opinion in Neurology, 2012, 25, 302-305.	3.6	6
318	Immunological and clinical consequences of treating a patient with natalizumab. Multiple Sclerosis Journal, 2012, 18, 335-344.	3.0	40
319	Immune Therapy of Multiple Sclerosis - Future Strategies. Current Pharmaceutical Design, 2012, 18, 4489-4497.	1.9	25
320	Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor+ Regulatory T Cells. Immunity, 2012, 37, 264-275.	14.3	184
321	The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis. Experimental Neurology, 2012, 238, 149-155.	4.1	37
322	CD4⁺T Cells Predominate in Cerebrospinal Fluid and Leptomeningeal and Parenchymal Infiltrates in Cerebral Amyloid Î²â€“Related Angiitis. Archives of Neurology, 2012, 69, 773-7.	4.5	42
323	Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor Î³. Brain, 2012, 135, 1586-1605.	7.6	51
324	Cytotoxic CD8+ T cells and CD138+ plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies. Journal of Neuroinflammation, 2012, 9, 160.	7.2	13

#	Article	IF	Citations
325	Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis. European Journal of Immunology, 2012, 42, 569-572.	2.9	29
326	Immune mechanisms of new therapeutic strategies in multiple sclerosisâ€"A focus on alemtuzumab. Clinical Immunology, 2012, 142, 25-30.	3.2	62
327	CD4+ CD25+ FoxP3+ regulatory T cells suppress cytotoxicity of CD8+ effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level. Journal of Neuroinflammation, 2012, 9, 41.	7.2	19
328	Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathologica, 2012, 123, 235-245.	7.7	104
329	TRPM2 Cation Channels Modulate T Cell Effector Functions and Contribute to Autoimmune CNS Inflammation. PLoS ONE, 2012, 7, e47617.	2.5	61
330	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Research and Therapy, 2011, 13, R75.	3.5	170
331	Expression of K2P5.1 potassium channels on CD4+T lymphocytes correlates with disease activity in rheumatoid arthritis patients. Arthritis Research and Therapy, 2011, 13, R21.	3.5	25
332	Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2036-2044.	2.6	39
333	Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. Journal of Autoimmunity, 2011, 36, 106-114.	6.5	77
334	Active immunization with proteolipid protein (190-209) induces ascending paralysing experimental autoimmune encephalomyelitis in C3H/HeJ mice. Journal of Immunological Methods, 2011, 367, 27-32.	1.4	4
335	Transforming multiple sclerosis trials into practical reality. Lancet Neurology, The, 2011, 10, 493-494.	10.2	3
336	Ion channels in autoimmune neurodegeneration. FEBS Letters, 2011, 585, 3836-3842.	2.8	27
337	Janus head: the dual role of HLA-G in CNS immunity. Cellular and Molecular Life Sciences, 2011, 68, 407-416.	5.4	11
338	Natalizumab restores evoked potential abnormalities in patients with relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 198-203.	3.0	27
339	Collateral neuronal apoptosis in CNS gray matter during an oligodendrocyteâ€directed CD8⁺ T cell attack. Glia, 2010, 58, 469-480.	4.9	27
340	Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood, 2010, 115, 3835-3842.	1.4	315
341	The role of dendritic cells in CNS autoimmunity. Journal of Molecular Medicine, 2010, 88, 535-544.	3.9	70
342	Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice â€" Implications for neuroinflammatory models. Journal of Immunological Methods, 2010, 354, 80-84.	1.4	20

#	Article	IF	Citations
343	FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. Journal of Neuroimmunology, 2010, 225, 137-142.	2.3	51
344	Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation. Neurobiology of Disease, 2010, 37, 483-490.	4.4	37
345	Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1A. Neurobiology of Disease, 2010, 38, 78-84.	4.4	15
346	Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. Glia, 2010, 58, 80-92.	4.9	59
347	Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. European Journal of Immunology, 2010, 40, 3581-3590.	2.9	56
348	Upregulation of K_{2P}5.1 potassium channels in multiple sclerosis. Annals of Neurology, 2010, 68, 58-69.	5.3	60
349	Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9). Experimental & Translational Stroke Medicine, 2010, 2, 14.	3.2	19
350	From the Background to the Spotlight: TASK Channels in Pathological Conditions. Brain Pathology, 2010, 20, 999-1009.	4.1	67
351	Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine. Drug Design, Development and Therapy, 2010, 4, 117.	4.3	7
352	Lessons from the Past and Future Approaches for Immunologic Therapies in Multiple Sclerosis. Blue Books of Neurology, 2010, , 388-426.	0.1	0
353	An Imbalance of Two Functionally and Phenotypically Different Subsets of Plasmacytoid Dendritic Cells Characterizes the Dysfunctional Immune Regulation in Multiple Sclerosis. Journal of Immunology, 2010, 184, 5368-5374.	0.8	62
354	Stromal Interaction Molecules 1 and 2 Are Key Regulators of Autoreactive T Cell Activation in Murine Autoimmune Central Nervous System Inflammation. Journal of Immunology, 2010, 184, 1536-1542.	0.8	96
355	Postpartum disease activity and breastfeeding in multiple sclerosis revisited. Neurology, 2010, 75, 392-393.	1.1	6
356	Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve. Experimental Neurology, 2010, 222, 153-160.	4.1	26
357	Glatiramer Acetate Attenuates Pro-Inflammatory T Cell Responses but Does Not Directly Protect Neurons from Inflammatory Cell Death. American Journal of Pathology, 2010, 177, 3051-3060.	3.8	10
358	Therapeutic Approaches to Multiple Sclerosis. BioDrugs, 2010, 24, 249-274.	4.6	22
359	Therapeutic Approaches to Multiple Sclerosis. BioDrugs, 2010, 24, 317-330.	4.6	24
360	B7-H1-Deficiency Enhances the Potential of Tolerogenic Dendritic Cells by Activating CD1d-Restricted Type II NKT Cells. PLoS ONE, 2010, 5, e10800.	2.5	24

#	Article	IF	Citations
361	Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis. PLoS ONE, 2010, 5, e15478.	2.5	21
362	PD-1 Regulates Neural Damage in Oligodendroglia-Induced Inflammation. PLoS ONE, 2009, 4, e4405.	2.5	16
363	CD8⁺T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB Journal, 2009, 23, 3659-3673.	0.5	85
364	T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible. Journal of Leukocyte Biology, 2009, 86, 273-281.	3.3	76
365	Cytotoxic CD8⁺T Cellâ€"Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death. Journal of Neuroscience, 2009, 29, 15397-15409.	3.6	78
366	CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain, 2009, 132, 1236-1246.	7.6	131
367	TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain, 2009, 132, 2501-2516.	7.6	88
368	Iatrogenic immunosuppression with biologics in MS. Neurology, 2009, 73, 1346-1347.	1.1	11
369	Antigen-Specific Blockade of Lethal CD8 T-Cell Mediated Autoimmunity in a Mouse Model of Multiple Sclerosis. Journal of Immunology, 2009, 182, 6569-6575.	0.8	13
370	Intracerebral Dendritic Cells Critically Modulate Encephalitogenic versus Regulatory Immune Responses in the CNS. Journal of Neuroscience, 2009, 29, 140-152.	3.6	65
371	The neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice. Neurobiology of Disease, 2009, 33, 1-11.	4.4	51
372	The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy. Neurobiology of Disease, 2009, 33, 96-103.	4.4	13
373	Intercellular exchanges of membrane fragments (trogocytosis) between human muscle cells and immune cells: A potential mechanism for the modulation of muscular immune responses. Journal of Neuroimmunology, 2009, 209, 131-138.	2.3	20
374	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmunity Reviews, 2009, 9, 82-89.	5.8	62
375	Specific central nervous system recruitment of HLAâ€G⁺ regulatory T cells in multiple sclerosis. Annals of Neurology, 2009, 66, 171-183.	5.3	67
376	The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE. European Journal of Immunology, 2009, 39, 1536-1543.	2.9	24
377	Comment on â€œFunctional consequences of Kv1.3 ion channel rearrangement into the immunological synapseâ€• Immunology Letters, 2009, 125, 156-157.	2.5	3
378	The future of multiple sclerosis therapyâ˜†. Pharmacological Research, 2009, 60, 207-211.	7.1	22

#	Article	IF	Citations
379	Multiple sclerosis therapeutics. Neurology, 2009, 72, 1008-1015.	1.1	65
380	Accelerated Course of Experimental Autoimmune Encephalomyelitis in PD-1-Deficient Central Nervous System Myelin Mutants. American Journal of Pathology, 2009, 174, 2290-2299.	3.8	39
381	Collateral Bystander Damage by Myelin-Directed CD8+ T Cells Causes Axonal Loss. American Journal of Pathology, 2009, 175, 1160-1166.	3.8	75
382	Immunotherapy of multiple sclerosis. Acta Neuropsychiatrica, 2009, 21, 27-34.	2.1	2
383	Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis. Open Rheumatology Journal, 2009, 2, 81-88.	0.2	30
384	The two-pore domain potassium channel TASK3 functionally impacts glioma cell death. Journal of Neuro-Oncology, 2008, 87, 263-270.	2.9	34
385	Immunomodulatory treatment strategies in multiple sclerosis. Journal of Neurology, 2008, 255, 15-21.	3.6	27
386	The metalloproteinaseâ€disintegrin ADAM10 is exclusively expressed by type I muscle fibers. Muscle and Nerve, 2008, 38, 1049-1051.	2.2	2
387	B7â€H1 restricts neuroantigenâ€specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. European Journal of Immunology, 2008, 38, 1734-1744.	2.9	72
388	Human muscle cells express the costimulatory molecule B7â€H3, which modulates muscleâ€“immune interactions. Arthritis and Rheumatism, 2008, 58, 3600-3608.	6.7	19
389	Idiopathic Inflammatory Myopathies: Current and Future Therapeutic Options. Neurotherapeutics, 2008, 5, 548-557.	4.4	23
390	CNS inflammation and neuronal degeneration is aggravated by impaired CD200â€“CD200R-mediated macrophage silencing. Journal of Neuroimmunology, 2008, 194, 62-69.	2.3	89
391	Human myoblasts modulate the function of antigen-presenting cells. Journal of Neuroimmunology, 2008, 200, 62-70.	2.3	13
392	Pharmacological Treatment of Early Multiple Sclerosis. Drugs, 2008, 68, 73-83.	10.9	41
393	The role of regulatory T cells in multiple sclerosis. Nature Clinical Practice Neurology, 2008, 4, 384-398.	2.5	189
394	The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. Human Immunology, 2008, 69, 797-804.	2.4	36
395	Altered neuronal expression of TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation. Neuroscience Letters, 2008, 446, 133-138.	2.1	12
396	TWIK-related Acid-sensitive K+ Channel 1 (TASK1) and TASK3 Critically Influence T Lymphocyte Effector Functions. Journal of Biological Chemistry, 2008, 283, 14559-14570.	3.4	89

#	Article	IF	Citations
397	Detrimental Contribution of the Immuno-Inhibitor B7-H1 to Rabies Virus Encephalitis. Journal of Immunology, 2008, 180, 7506-7515.	0.8	89
398	A Î²-Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis. PLoS ONE, 2008, 3, e3149.	2.5	76
399	Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells. PLoS ONE, 2008, 3, e3319.	2.5	49
400	Expression of Molecules Involved in Fetal-Maternal Tolerance Allows Human Mesenchymal Stem Cells to Engraft at High Levels across Immunologic Barriers. Blood, 2008, 112, 3480-3480.	1.4	5
401	The trials and errors in MS therapy. International MS Journal, 2008, 15, 79-90.	0.3	7
402	HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood, 2007, 110, 568-577.	1.4	162
403	Fast track to becoming a regulatory T cell: â€œtrogocytosisâ€•of immune-tolerogenic HLA-G. Blood, 2007, 109, 1796-1797.	1.4	8
404	HLA-G in the Nervous System. Human Immunology, 2007, 68, 286-293.	2.4	22
405	The Genetic Influence of the Nonclassical MHC Molecule HLA-G on Multiple Sclerosis. Human Immunology, 2007, 68, 422-425.	2.4	32
406	Oral Disease-Modifying Treatments for Multiple Sclerosis. CNS Drugs, 2007, 21, 483-502.	5.9	28
407	Modulation of T-effector function by imatinib at the level of cytokine secretion. Experimental Hematology, 2007, 35, 1266-1271.	0.4	31
408	Immune-refractory cancers and their little helpersâ€”An extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. Seminars in Cancer Biology, 2007, 17, 459-468.	9.6	56
409	The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiology of Disease, 2007, 25, 665-674.	4.4	33
410	Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G. Journal of Neuroimmunology, 2007, 187, 205-211.	2.3	42
411	WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?. Acta Neuropathologica, 2007, 114, 111-119.	7.7	55
412	Treatment of active secondary progressive multiple sclerosis with treosulfan. Journal of Neurology, 2007, 254, 884-889.	3.6	23
413	Multiple sclerosis therapy: An update on recently finished trials. Journal of Neurology, 2007, 254, 1473-1490.	3.6	11
414	Review of Novel Immunotherapeutic Strategies for MS. , 2007, , 289-338.		0

#	Article	IF	Citations
415	No effect of immunomodulatory therapy in focal epilepsy with positive glutamate receptor type 3â€"antibodies. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 350-354.	2.0	8
416	The inflamed peripheral nervous system: update on immune therapies. Current Opinion in Neurology, 2006, 19, 433-436.	3.6	15
417	The role of leukemia-derived B7-H1 (PD-L1) in tumorâ€"T-cell interactions in humans. Experimental Hematology, 2006, 34, 888-894.	0.4	47
418	Multiple sclerosis: advances, excitements, disenchantments. Lancet Neurology, The, 2006, 5, 2-3.	10.2	3
419	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responsesin vitro. International Journal of Cancer, 2006, 119, 317-327.	5.1	276
420	Immune Cells Contribute to Myelin Degeneration and Axonopathic Changes in Mice Overexpressing Proteolipid Protein in Oligodendrocytes. Journal of Neuroscience, 2006, 26, 8206-8216.	3.6	109
421	The Contribution of TWIK-Related Acid-Sensitive K+-Containing Channels to the Function of Dorsal Lateral Geniculate Thalamocortical Relay Neurons. Molecular Pharmacology, 2006, 69, 1468-1476.	2.3	58
422	Expression of tollâ€like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates ILâ€8 release, and upâ€regulation of NKG2Dâ€ligands. FASEB Journal, 2006, 20, 118-120.	0.5	81
423	Muscle-derived positive and negative regulators of the immune response. Current Opinion in Rheumatology, 2005, 17, 714-719.	4.3	29
424	Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-Î² in vitro and in vivo: rationale for the therapy of multiple sclerosis. Journal of Neuroimmunology, 2005, 159, 155-164.	2.3	82
425	Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. Journal of Neuroimmunology, 2005, 168, 128-137.	2.3	60
426	A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Annals of Neurology, 2005, 58, 50-57.	5.3	203
427	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. Journal of Neuroscience, 2005, 25, 2537-2546.	3.6	150
428	Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain, 2005, 128, 2689-2704.	7.6	170
429	Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends in Immunology, 2005, 26, 373-380.	6.8	175
430	Diffusion Abnormality in Baloâ€™s Concentric Sclerosis: Clues for the Pathogenesis. European Neurology, 2005, 53, 42-44.	1.4	26
431	Antigen recognition properties of a VÎ³1.3VÎ´2-T-cell receptor from a rare variant of polymyositis. Journal of Neuroimmunology, 2004, 152, 168-175.	2.3	9
432	Interferon-Î² enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Journal of Neuroimmunology, 2004, 155, 172-182.	2.3	249

#	Article	IF	Citations
433	Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Seminars in Cancer Biology, 2003, 13, 343-351.	9.6	40
434	Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. Journal of Neuroimmunology, 2003, 144, 28-37.	2.3	27
435	Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. Journal of Neuroimmunology, 2003, 138, 132-143.	2.3	44
436	The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. Journal of Neuroimmunology, 2003, 140, 177-187.	2.3	13
437	Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia, 2003, 44, 296-301.	4.9	34
438	Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. Human Immunology, 2003, 64, 1050-1056.	2.4	28
439	Human muscle cells express a B7â€related molecule, B7â€H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB Journal, 2003, 17, 1-16.	0.5	95
440	Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opinion on Investigational Drugs, 2003, 12, 689-712.	4.1	32
441	Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain, 2003, 126, 1026-1035.	7.6	112
442	The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain, 2003, 126, 176-185.	7.6	80
443	Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Research, 2003, 63, 7462-7.	0.9	312
444	Advances in pathogenic concepts and therapeutic agents in Rasmussenâ€™s encephalitis. Expert Opinion on Investigational Drugs, 2002, 11, 981-989.	4.1	25
445	An Autoreactive Î³Î´ TCR Derived from a Polymyositis Lesion. Journal of Immunology, 2002, 169, 515-521.	0.8	38
446	A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape. Journal of Immunology, 2002, 168, 4772-4780.	0.8	310
447	Therapeutic Approaches in Multiple Sclerosis. BioDrugs, 2002, 16, 183-200.	4.6	167
448	Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis. Annals of Neurology, 2002, 51, 311-318.	5.3	353
449	The ups and downs of multiple sclerosis therapeutics. Annals of Neurology, 2001, 49, 281-284.	5.3	61
450	Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Annals of Neurology, 2000, 48, 679-684.	5.3	88